Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
Status:
Active, not recruiting
Trial end date:
2021-10-15
Target enrollment:
Participant gender:
Summary
The main purpose of the study was to determine the onset of Mavenclad® action by frequent
magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in
participants with highly active relapsing multiple sclerosis (MS).